Biomerica, Inc.

Equities

BMRA

US09061H3075

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 15:53:10 2024-05-14 EDT			5-day change	1st Jan Change
0.592 ^USD	-1.82%		+5.08%	-52.00%

04-29	Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE	MT
04-29	Biomerica and UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement	CI

Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023

October 12, 2023 at 05:16 pm

Biomerica, Inc. reported earnings results for the first quarter ended August 31, 2023. For the first quarter, the company reported sales was USD 1.71 million compared to USD 1.64 million a year ago. Net loss was USD 1.13 million compared to USD 2.07 million a year ago.

Basic loss per share from continuing operations was USD 0.07 compared to USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.16 a year ago.

Latest news about Biomerica, Inc.

Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE	04-29	MT
Biomerica and UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement	04-29	CI
Biomerica Provides Update on inFoods IBS Expansion	04-15	CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	04-12	CI
Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board	02-21	CI
Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors	01-23	CI
Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	01-16	CI
Top Premarket Decliners	12-19	MT
Biomerica Shares Rise After FDA 510(k) Clearance for H Pylori Bacteria Test	12-18	DJ
Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria	12-18	CI
Biomerica, Inc. Expands in Foods IBS Reach with Addition of Several New GI Groups	11-08	CI
Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-12	CI
Biomerica Says Dubai Approves Insurance Reimbursement for Colorectal Disease Screening Test	23-09-26	MT
Jack Kenny Joins Biomerica?S Board of Directors	23-08-28	CI
Biomerica, Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	23-08-25	CI
Biomerica's Colorectal Disease Screening Test to be Available in CVS Stores in September	23-08-03	MT
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Growth Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Growth Index	23-06-23	CI
Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients	23-06-21	CI
Certain Stock Options of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI
Certain Common Stock of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI
Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome	23-05-18	CI
Biomerica, Inc. Announces inFoods IBS Test Now Available at Gastro Health	23-04-17	CI

Chart Biomerica, Inc.

Duration

Period

More charts

Company Profile

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physiciansâ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Companyâs two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - EF Hutton Investor Conference

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOMERICA, INC.	-52.00%	10.14M
ABBOTT LABORATORIES	-5.88%	182B
MEDTRONIC PLC	+2.09%	111B
BECTON, DICKINSON AND COMPANY	-3.63%	68.48B
DEXCOM, INC.	+1.42%	49.69B
CENCORA, INC.	+7.80%	44.46B
HOYA CORPORATION	+2.33%	40.67B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.48%	31.22B
WEST PHARMACEUTICAL SERVICES, INC.	+0.51%	26.09B
TERUMO CORPORATION	+15.30%	25.32B

Other Medical Equipment, Supplies & Distribution